Smoking is associated with a lower incidence of Parkinson's disease (PD), which might be related to a neuroprotective action of nicotine. Postmortem studies have shown a decrease of cerebral nicotinic acetylcholine receptors (nAChRs) in PD. In this study, we evaluated the decrease of nAChRs in PD in vivo using positron emission tomography (PET), and we explored the relationship between nAChRs density and PD severity using both clinical scores and the measurement of striatal dopaminergic function. Thirteen nondemented patients with PD underwent two PET scans, one with 6-[ 18 F]fluoro-3,4-dihydroxy-L-phenylalanine (6-[ 18 F]fluoro-L-DOPA) to measure the dopaminergic function and another with 2-[ 18 F]fluoro-3-[2(S)-2-azetidinylmethoxy]pyridine (2-[ 18 F]fluoro-A-85380), a radiotracer with high affinity for the nAChRs. Distribution volumes (DVs) of 2-[ 18 F]fluoro-A-85380 measured in the PD group were compared with those obtained from six nonsmoking healthy controls, with regions-of-interest and voxel-based approaches. Both analyses showed a significant (P < 0.05) decrease of 2-[ 18 F]fluoro-A-85380 DV in the striatum (À10%) and substantia nigra (À14.9%) in PD patients. Despite the wide range of PD stages, no correlation was found between DV and the clinical and PET markers of PD severity.
Introduction
Parkinson's disease (PD) is a neurodegenerative movement disorder that is characterized by a progressive loss of the nigrostriatal dopaminergic neurons leading to a severe dopamine depletion state. In addition to the decline of the dopaminergic function, other neurotransmitter systems are involved in PD, including the nicotinic cholinergic system (Jellinger, 1991) . There is now accumulating evidence that there are significant declines in nicotinic acetylcholine receptors (nAChRs) in the postmortem brains of both demented and nonde-mented patients with PD (Aubert et al, 1992; Rinne et al, 1991; Quik, 2004) . Moreover, converging evidence suggests that nAChRs could be potential targets for PD therapy and neuroprotective strategies. For example, numerous studies have shown that the stimulation of the nicotinic receptors located on presynaptic dopaminergic neurons by nicotine increases dopamine release in the striatum Salminen et al, 2004) . In parallel, smoking markedly reduces the risk of developing PD (Allam et al, 2004) . Finally, nicotine protects against neuronal insults in experimental models of PD (Jeyarasasingam et al, 2002; Parain et al, 2003; Quik et al, 2006) . Hence, a deeper knowledge with regard to the nAChRs located in the basal ganglia and the changes related to PD is necessary.
Neuronal nAChRs are pentameric ligand-gated ion channels composed of a-subunits (homomeric receptors) or of a-(a2 to a7) and b-subunits (b2 to b4) (heteromeric receptors). The a4b2 nAChRs are the prominent subtype in the human brain (Gotti and Clementi, 2004) . Nontoxic and selective ligands of nicotinic receptors have been recently developed and validated in humans for the assessment of cerebral nAChRs with SPECT (single photon emission computed tomography) or positron emission tomography (PET) imaging. Among those, the derivatives of 3-[2(S)-2-azetidinylmethoxy]pyridine (A-85380) are ligands with a high affinity for the b2* nAChR subtype (Gao et al, 2008; Pimlott et al, 2004; Quik et al, 2004; Schmaljohann et al, 2006 ) . Recent SPECT studies (Fujita et al 2006; Oishi et al, 2007) using 5-[ 123 I]iodo-A-85380 have found a decrease of nAChRs in both the cortical and subcortical regions in the brain of PD patients.
A-85380 has also been radiolabeled with fluorine-18 and characterized for PET imaging of nicotinic receptors in the human brain (Dollé et al, 1999; Koren et al, 1998; Valette et al, 1999a, b; Bottlaender et al, 2003) . Among these compounds, 2-[ 18 F]fluoro-A-85380 has a high affinity for the a4b2* subtype (Gao et al, 2008) and is the most studied PET radioligand.
This study aimed at measuring the in vivo cerebral loss of nAChRs in 13 nondemented PD patients using 2-[ 18 F]fluoro-A-85380 and highresolution imaging with PET. We also investigated the relationship between nAChRs cerebral distributions and PD severity using the clinical variables of PD patients and the measurement of striatal dopaminergic function with PET and 6-[ 18 F]fluoro-3,4-dihydroxy-L-phenylalanine (6-[ 18 F] fluoro-L-DOPA) reflecting dopamine synthesis and vesicular storage capacity (Brooks et al, 2003) .
Materials and methods

Subjects
Thirteen nondemented PD patients, aged 61.2 ± 10.8 years (mean±s.d.) were enrolled (Table 1) . All subjects satisfied the United Kingdom Parkinson's Disease Society Brain Bank Diagnostic criteria for the clinical diagnosis of idiopathic PD (Hughes et al, 1992) . Symptoms duration ranged from 0.75 to 19 years and the Hoehn and Yahr stage varied from I to IV, when off medication. All but one, were on anti-Parkinsonian medication. None of them had been treated with drugs interacting with the cholinergic system in the 2 months before the study. None of the PD patients had dementia according to the MMSE (Mini-Mental State Examination) score; they all scored higher than 26/30, except patient no. 4 who scored 25. However, this Polish patient had trouble with the French language, which explained most of his mistakes. Five patients had never smoked. Eight patients had quit 7 to 26 years earlier.
The control group consisted of six nonsmoking healthy volunteers, aged 61.2 ± 13.9 years (range 37 to 74, three men and three women) without any psychiatric or neurologic illness or cholinergic medication. All of them had a negative plasma cotinine determination and a normal brain magnetic resonance imaging (MRI). There was no significant difference in age (t-test, P = 0.8) or gender (w 2 , P = 0.88) between the two groups. This study was approved by the local ethical committee. Written informed consent was obtained from all participants.
Study Design
The severity of PD was measured using the UPDRS (Unified Parkinson's Disease Rating Scale) motor score Thobois (2006) ; H&Y. Purdue Pegboard = number of digits in 30 secs. Hand-arm = time to perform 20 movements. Global cognitive efficiency was evaluated using the MMSE according to Folstein et al (1975) .
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and timed motor tests (Purdue Pegboard, hand-arm tests) in the defined 'off' condition (i.e., at least 12 h after the last anti-Parkinsonian medications) (Defer et al, 1999) . This evaluation was performed by one neurologist, an expert in movement disorders. He was blinded to the PET results. All subjects underwent a T 1 -weighted MR scan and a 2-[ 18 F]fluoro-A-85380 PET scan on the same day. The reduction of striatal dopaminergic function was assessed in PD patients using 6-[ 18 F]fluoro-L-DOPA PET on a separate day. All PET studies were carried out using an ECAT, EXACT HR + tomograph (Siemens Medical Solutions, Knoxville, TN, USA), which collected 63 simultaneous 2.4-mm-thick axial slices in a three-dimensional mode, with an isotropic intrinsic resolution of 4.5 mm. A thermolabile plastic face mask ensured a stable position of the head. Before the tracer injection, a transmission scan ([ 68 Ge] rods; 15 mins) was recorded in each individual to correct for g-ray attenuation.
Magnetic Resonance Imaging and Anatomic Volumes-of-Interest
Magnetic resonance imaging scans were performed on a 1.5 T imager (Signa, General Electric, Milwaukee, WI, USA). A T 1 -weighted inversion-recovery sequence in a three-dimensional mode was used to generate anatomic images and anatomic volumes-of-interest (VOIs). Magnetic resonance imaging parameters included 124 axial slices of 1.2-mm thickness, a field of view of 24 cm, and an acquisition matrix of 256 Â 256, with a voxel size of 0.93 Â 0.93 Â 1.2 mm 3 .
Volumes-of-interest were drawn manually on each patient's T 1 -weighted MRI using the BrainVisa software (http://brainvisa.info). It was performed by the same physician blinded to subject information. The same method was used to delineate VOIs in all subjects. Frontal (8.5 ± 0.6 mL), parietal (6.5 ± 0.7 mL), occipital (12.5 ± 1.0 mL), and temporal (6.6±0.6 mL) cortical VOIs were outlined following the gray matter ribbon with the identification of key sulci. Others VOIs included the cerebellum (23.9±1.8 mL), corpus callosum (9.0± 1.3 mL), caudate (2.7±0.2 mL), putamen (3.7±0.3 mL), thalamus (5.7 ± 0.6 mL), substantia nigra (2.3 ± 0.2 mL), pons (8.1 ± 0.8 mL), hippocampus (3.1 ± 0.5 mL), and amygdala (1.2±0.2 mL). All VOIs were automatically one-voxel thickness eroded. We verified that there was no significant difference in cortical and subcortical volumes between patients and age-matched controls (t-test, all P > 0.05).
6-[ 18 F]fluoro-L-DOPA Positron Emission Tomography Acquisition and Analysis
All dopaminergic medications were stopped at least 12 h before the scan (Brooks et al, 2003; Ribeiro et al, 2002) . All patients received 100 mg of carbidopa, a peripheral decarboxylase inhibitor, 1 h before tracer injection. Nine frames were acquired over 90 mins, after tracer intravenous injection (159.7±31.2 MBq). Positron emission tomography scans were reconstructed with filtered back projection with a ramp filter producing images with a resolution of 6.8 mm full-width at half-maximum. Positron emission tomography images were corrected for scatter, g-ray attenuation, and fluorine-18 decay. The voxel size was 2.4 Â 2.4 Â 2.4 mm 3 .
A parametric image of 6-[ 18 F]fluoro-L-DOPA influx constant (K i , measured per min) was generated using the Patlak graphical analysis and occipital radioactivity as a nonspecific function (Patlak and Blasberg, 1985; Ribeiro et al, 2002) . The parametric image was coregistered with the individual MRI using a mutual information algorithm and a PET image obtained after staggered summation of dynamic images over 90 mins. K i values were measured in the striatum using the anatomic VOIs described above.
2-[ 18 F]fluoro-A-85380 Positron Emission Tomography Acquisition and Analysis
A-85380 was labeled with fluorine-18 by a no-carrier-added nucleophilic aromatic substitution (Dollé et al, 1999) . 2-[ 18 F]fluoro-A-85380 (188 ± 22 MBq; 2 to 3 nmol) was injected intravenously as a 1-min bolus. Positron emission tomography acquisition started 90 mins later and lasted for 2 h, a period in which the apparent steady state of 2-[ 18 F]fluoro-A-85380 was reached as shown by Gallezot et al (2005) and Mitkovski et al (2005) . Fifteen sequential frames were acquired with the acquisition duration ranging from 5 to 10 mins. Twenty venous blood samples were collected, initially every 5 mins during the first hour after injection, and then subsequently every 10 mins until the end of the PET emission (Picard et al, 2006) . Plasma radioactivity was measured in a g-counter (Cobra Quantum D5003, Perkin-Elmer, France). On the basis of the fact that the metabolites of 2-[ 18 F]fluoro-A-85380 do not cross the blood-brain barrier (unpublished data), we applied a metabolite correction only for the plasma as previously described (Gallezot et al, 2005) . Positron emission tomography emissions were reconstructed using the same procedure as that of the 6-[ 18 F]fluoro-L-DOPA PET. Correction for partial volume effects was not performed on PET data, considering that brain atrophy is not common in nondemented PD patients (Burton et al, 2004) . Moreover, there was no significant difference in cortical and subcortical volumes measured in PD patients and controls.
The distribution volume (DV) of 2-[ 18 F]fluoro-A-85380 was determined using a simplified method based on the ratio of brain tissue concentration to unchanged 2-[ 18 F]fluoro-A-85380 plasma concentration at equilibrium as defined by Mitkovski et al (2005) . However, venous plasma was used instead of arterial plasma in our series. This simplified approach has been previously validated in 10 subjects (5 PD patients and 5 controls) of our study. These subjects had dynamic PET scan acquisition, and arterial and venous blood collections started with the bolus administration of 2-[ 18 F]fluoro-A-85380, which enabled the calculation of DV with a two-tissue compartmental model analysis as described in Gallezot et al (2005) . We found that the DV values defined by the region-to-venous plasma ratio were strongly correlated with those obtained from a twotissue compartmental model analysis (data not shown). It showed that the venous blood sampling was an acceptable nAChRs in PD choice for input function and that 2-[ 18 F]fluoro-A-85380 DV values expressed by this ratio can be used to quantify cerebral nAChRs concentration.
Parametric images of 2-[ 18 F]fluoro-A-85380 DV were created using the BrainVisa software. For each frame collected during the last 30 mins of the emission scan, the radioactivity in each voxel was divided by the value of individually metabolite-corrected 2-[ 18 F]fluoro-A-85380 concentration in venous plasma measured at the same time point.
Statistical Analysis
The 2-[ 18 F]fluoro-A-85380 DV images were analyzed by combining an individual analysis using VOIs and a voxelbased approach using the Statistical Parametric Mapping software (SPM2, Wellcome Department of Cognitive Neurology, London, UK), which enables exploratory analysis of the entire brain volume without requiring an a priori hypothesis.
Distribution volume values in the VOIs were measured from the PET parametric image, after coregistration with the MRI. The DV values of the patients and controls were compared by an analysis of variance with post hoc t-tests. Spearman's rank test was used to study the relationship between DV values and the mean caudate and putamen K i , and between DV values and disease duration, the daily dose of levodopa and dopamine agonist and motor scores. Statistical tests were performed using StatView (SAS, Cary, NC, USA) and were considered significant at P < 0.05.
The SPM2 software implemented in Matlab 6.5 (Math-Works, Natick, MA, USA) was also used to localize mean group differences in 2-[ 18 F]fluoro-A-85380 DV between PD patients and controls throughout the entire brain volume. The DV images were spatially normalized to a standard anatomic orientation (Montreal Neurological Institute space) using an appropriate gray matter template; first, individual parametric images were registered to individual T 1 -weighted MRI, thereafter gray matter segmented MRI were normalized to the template, and finally the corresponding normalization coordinates were applied to DV images. Normalized images were smoothed using an isotropic Gaussian kernel of 8 mm to remove highfrequency noise from the images and to take into account anatomic differences between subjects. As each voxel contains a quantified DV value, no global normalization was applied. The SPM comparisons between patients and controls were performed using a two-sample t-test. The entire brain volume was initially assessed at a height threshold of uncorrected P < 0.001. Thereafter, a small volume correction was performed using a mask, including the midbrain and the basal ganglia, at a level of P < 0.05 corrected for multiple comparisons. This analysis was based on the hypothesis that a change in nAChRs density might appear in these regions according to postmortem findings in PD. Anatomic locations were obtained using the Anatomical Automatic Labeling software (http:// www.cyceron.fr/freeware).
Results
2-[ 18 F]fluoro-A-85380 Volume Of Interest Analysis
In controls, the greatest DV value was found in the thalamus. High-to-intermediate levels were observed in other regions, and the lowest DV values were found in the occipital cortex and corpus callosum (Table 2, Figure 1) .
In PD patients, there was no right-to-left asymmetry of DV values despite the asymmetry of motor symptoms. Accordingly, statistical tests were performed using DV values averaged over both hemispheres. Compared with controls, we found a widespread decrease of DV values in the PD patients, ranging from À0.4% in the occipital cortex to a À14.9% loss in the substantia nigra (Table 2) . After Figure 1 Axial, sagittal, and coronal mean PET images obtained from one control between 90 and 120 mins, after the injection of 2-[ 18 F]fluoro-A-85380. PET images are coregistered with MR images.
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Bonferroni correction, the decrease remained significant only in the substantia nigra (À14.9%, P = 0.02), putamen (À9.6%, P = 0.03), and caudate (À10.7%, P = 0.004). There was no significant difference between putamen and caudate DV values in PD patients.
2-[ 18 F]fluoro-A-85380 SPM Analysis
We found a significant bilateral decrease of DV in the striatum in the PD group (Table 3) . The analysis performed with a small volume correction (P < 0.05, corrected) showed a significant decrease of DV values in the substantia nigra ( Figure 2) . Conversely, whole-brain analysis showed no significant decrease of 2-[ 18 F]fluoro-A-85380 DV in the cerebral cortex of PD patients.
Correlations
No significant correlation was observed using both VOI (Spearman rank correlation test, all P > 0.05) and voxel-based analyses between regional DV values in the PD group and the markers of disease severity, namely the UPDRS motor score, the timed motor tests (Purdue Pegboard, hand-arm tests), the disease duration, and the daily dose of levodopa and dopamine agonists. In addition, there was no correlation between 6-[ 18 F]fluoro-L-DOPA K i values measured in the putamen and in the caudate nucleus (details in 
Discussion
Using 2-[ 18 F]fluoro-A-85380 and PET, we found a mild but significant reduction of the density of nAChRs in the striatum and substantia nigra of 13 nondemented PD patients. Despite the wide range of disease severity in these patients, we found no correlation between the different measures of PD severity and the reduction of nAChRs density. The cerebral distribution of nAChRs in our group of elderly healthy subjects is in agreement with previous studies in nonsmoking healthy volunteers (Gallezot et al, 2005; Kimes et al, 2003; Mitkovski et al, 2005; Picard et al, 2006) and is consistent with data obtained in vitro (Schmaljohann et al, 2006) . In PD patients, there is a trend toward a mild and widespread decrease of nAChRs density. However, both regional and voxel-based analyses showed that this reduction was significant only in the substantia nigra and striatum, i.e., the main structures involved in the neurodegenerative process in this disease. Interestingly, this result is in agreement with postmortem data. Although most of the latter studies did not distinguish between the different nAChRs subtypes, they consistently reported a reduction of nAChRs in the striatum of deceased PD patients (Aubert et al, 1992; Court et al, 2000; Perry et al, 1995; Rinne et al, 1991) . In addition, the substantia nigra was examined once (Perry et al, 1995) and a significant decrease of nAChRs was also reported. More recent postmortem studies (Pimlott et al, 2004; Quik et al, 2004; Schmaljohann et al, 2006) using more specific ligands, confirmed the previous studies showing a significant decrease of 5-[ 125 I]iodo-A-85380 and 2-[ 18 F]fluoro-A-85380 binding in the striatum of PD patients. The amplitude of this reduction (À30 to À50%) is greater than what we found in vivo. This might be related to methodological reasons; e.g., as there is no region devoid of nAChRs, we could not measure accurately NSB (nonspecific binding) and calculate a SB (specific binding) of 2-[ 18 F]fluoro-A-85380. As the PET tissue concentration is (NSB + SB), the SB decrease may have been underestimated. Alternatively, it is unclear whether postmortem studies have included PD patients with cognitive impairment. Demented patients have a more severe decrease of nAChRs than nondemented PD patients (Court et al, 2000; Rinne et al, 1991) . As only Although most studies converge to show a reduction of nAChRs density in the nigrostriatal system in PD, an emerging question is whether these changes are related to disease progression. We found no correlation between DV values and the different clinical markers of PD progression, including the amount of medication taken by the subjects, nor with the loss of 6-[ 18 F]fluoro-L-DOPA uptake in the putamen of these patients. Moreover, the reduction of nAChRs density was similar in the caudate and putamen, as well as in the left and right hemispheres, which differs from the gradient of the reduction of 6-[ 18 F]fluoro-L-DOPA uptake. One possible explanation for this result might be related to the subtypes of nAChRs, which are directly involved in the neuro-degenerative process. The decrease of 2-[ 18 F]fluoro-A-85380 DV reflects a reduction of heteromeric nAChRs as this tracer has a very low affinity for the homomeric a7 subtypes (Deuther -Conrad et al, 2004) . Among the heteromeric nAChRs, 2-[ 18 F]fluoro-A-85380 shows a selectivity for a4b2 over a3b4 receptors (Deuther-Conrad et al, 2004) , whereas its affinity for the other less abundant a*Àb2 subtypes remains to be established (Gao et al, 2008) . As 5-[ 123 I]iodo-A-85380, our tracer might interact with a6b2 subtypes (Kulak et al, 2002) . Recent studies have shown that the striatal a6b2-containing nAChRs, especially the a4a6b2b3 subtype, are particularly susceptible to nigrostriatal damage (Bohr et al, 2005; Bordia et al, 2007) , suggesting that they are located primarily on striatal dopaminergic terminals. Conversely, Quik et al (2004) found a dissociation between the severity of the loss of dopaminergic neurons and the binding of 5-[ 125 I]iodo-A-85380 in the putamen of postmortem Parkinsonian brains. Moreover, several studies suggest that a4b2 nAChRs are not only distributed on dopaminergic neurons but also on other neurons in the striatum, which remain unaffected by the degenerative process . Taken together, these findings may explain the lack of correlation between the 2-[ 18 F]fluoro-A-85380 DV values and the 6-[ 18 F]fluoro-L-DOPA uptake.
Eventually, it has been suggested that nAChRs, especially in the cerebral cortex, might be involved in the cognitive deterioration of PD patients (Rinne et al, 1991; Whitehouse et al, 1988) . In our series of 13 nondemented patients, 2-[ 18 F]fluoro-A-85380 DV was reduced by an average of 5% in the cortical regions, which did not reach statistical significance. In their study of 10 nondemented patients Fujita et al (2006) , found a similar reduction (À6% on average) of cortical binding of 5-[ 123 I]iodo-A-85380. In addition, Oishi et al (2007) reported a decrease of 5-[ 123 I]iodo-A-85380 DV in the cerebral cortex of 10 nondemented PD patients that only reached significance in the frontal cortex. These slight discrepancies might be related to methodological reasons, such as the use of two different derivates of A-85380, the blood sampling and the plasma analysis, or differences between PET and SPECT procedures, which do not have the same resolution and accuracy. Alternatively, this might simply show individual variations in three different small groups of patients. It could be hypothesized that some individuals have a more severe reduction of cortical nAChRs, which might be predictive of future dementia. Further longitudinal studies are needed to confirm such a hypothesis. Nevertheless, considering the high affinity of 2-[ 18 F]fluoro-A-85380 for the a4b2 nAChRs, the most widespread nAChRs population in the cortex, this ligand has a great potential for investigating the relationship between cognitive deficits and nAChRs density in Parkinsonian patients.
